Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Immunol ; 206(4): 686-699, 2021 02 15.
Artículo en Inglés | MEDLINE | ID: mdl-33419770

RESUMEN

East Coast fever (ECF), caused by Theileria parva, is the most important tick-borne disease of cattle in sub-Saharan Africa. Practical disadvantages associated with the currently used live-parasite vaccine could be overcome by subunit vaccines. An 80-aa polypeptide derived from the C-terminal portion of p67, a sporozoite surface Ag and target of neutralizing Abs, was the focus of the efforts on subunit vaccines against ECF and subjected to several vaccine trials with very promising results. However, the vaccination regimen was far from optimized, involving three inoculations of 450 µg of soluble p67C (s-p67C) Ag formulated in the Seppic adjuvant Montanide ISA 206 VG. Hence, an improved formulation of this polypeptide Ag is needed. In this study, we report on two nanotechnologies that enhance the bovine immune responses to p67C. Individually, HBcAg-p67C (chimeric hepatitis B core Ag virus-like particles displaying p67C) and silica vesicle (SV)-p67C (s-p67C adsorbed to SV-140-C18, octadecyl-modified SVs) adjuvanted with ISA 206 VG primed strong Ab and T cell responses to p67C in cattle, respectively. Coimmunization of cattle (Bos taurus) with HBcAg-p67C and SV-p67C resulted in stimulation of both high Ab titers and CD4 T cell response to p67C, leading to the highest subunit vaccine efficacy we have achieved to date with the p67C immunogen. These results offer the much-needed research depth on the innovative platforms for developing effective novel protein-based bovine vaccines to further the advancement.


Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Nanotecnología/métodos , Vacunas Antiprotozoos/inmunología , Theileria parva/fisiología , Theileriosis/inmunología , Enfermedades por Picaduras de Garrapatas/inmunología , Animales , Anticuerpos Antiprotozoarios/sangre , Bovinos , Virus de la Hepatitis B/química , Virus de la Hepatitis B/genética , Ratones , Aceite Mineral/administración & dosificación , Nanopartículas/química , Proteínas Protozoarias/genética , Vacunas Antiprotozoos/genética , Células RAW 264.7 , Dióxido de Silicio/química , Garrapatas , Vacunación , Vacunas de Subunidad , Proteínas del Núcleo Viral/química , Proteínas del Núcleo Viral/genética
2.
Proc Natl Acad Sci U S A ; 94(10): 5119-24, 1997 May 13.
Artículo en Inglés | MEDLINE | ID: mdl-9144200

RESUMEN

When T cells become infected by the parasite Theileria parva, they acquire a transformed phenotype and no longer require antigen-specific stimulation or exogenous growth factors. This is accompanied by constitutive interleukin 2 (IL-2) and IL-2 receptor expression. Transformation can be reversed entirely by elimination of the parasites using the specific drug BW720c. Extracellular signal-regulated kinase and jun NH2-terminal kinase (JNK) are members of the mitogen-activated protein kinase family, which play a central role in the regulation of cellular differentiation and proliferation and also participate in the regulation of IL-2 and IL-2 receptor gene expression. T. parva was found to induce an unorthodox pattern of mitogen-activated protein kinase expression in infected T cells. JNK-1 and JNK-2 are constitutively active in a parasite-dependent manner, but have altered properties. In contrast, extracellular signal-regulated kinase-2 is not activated even though its activation pathway is functionally intact. Different components of the T cell receptor (TCR)-dependent signal transduction pathways also were examined. The TCRzeta or CD3epsilon chains were found not to be phosphorylated and T. parva-transformed T cells were resistant to inhibitors that block the early steps of T cell activation. Compounds that inhibit the progression of T cells to proliferation, however, were inhibitory. Our data provide the first example, to our knowledge, for parasite-mediated JNK activation, and our findings strongly suggest that T. parva not only lifts the requirement for antigenic stimulation but also entirely bypasses early TCR-dependent signal transduction pathways to induce continuous proliferation.


Asunto(s)
Antiprotozoarios/farmacología , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Activación de Linfocitos , Proteínas Quinasas Activadas por Mitógenos , Naftoquinonas/farmacología , Proteínas Quinasas/metabolismo , Linfocitos T/fisiología , Linfocitos T/parasitología , Tacrolimus/análogos & derivados , Theileria parva/fisiología , 8-Bromo Monofosfato de Adenosina Cíclica/farmacología , Animales , Línea Celular , Activación Enzimática/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Humanos , Inmunosupresores/farmacología , Indoles/farmacología , Proteínas Quinasas JNK Activadas por Mitógenos , Cinética , Ganglios Linfáticos/inmunología , Maleimidas/farmacología , Proteína Quinasa 9 Activada por Mitógenos , Polienos/farmacología , Proteína Quinasa C/antagonistas & inhibidores , Complejo Receptor-CD3 del Antígeno de Linfocito T/aislamiento & purificación , Complejo Receptor-CD3 del Antígeno de Linfocito T/fisiología , Sirolimus , Linfocitos T/inmunología , Tacrolimus/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA